Understanding how UBE2J1 affects the breakdown of the androgen receptor in prostate cancer.
Unveiling the Role of UBE2J1 as the E2 Ubiquitin Conjugating Enzyme in Androgen Receptor Degradation
This study is looking at how a protein called UBE2J1 affects the levels of the androgen receptor, which is important for treating prostate cancer, and aims to find new ways to help patients whose cancer isn't responding to current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11235246 on NIH RePORTER |
What this research studies
This research investigates the role of the UBE2J1 enzyme in the degradation of the androgen receptor (AR), which is crucial for the treatment of prostate cancer. The study aims to address the challenge of treatment resistance by exploring how UBE2J1 influences AR levels and signaling. By examining the effects of UBE2J1 loss in prostate cancer patients, the research seeks to develop new therapeutic strategies that could restore AR degradation and inhibit tumor growth. Patients may benefit from novel treatments that target this specific mechanism of resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are prostate cancer patients who exhibit resistance to androgen receptor-targeted therapies.
Not a fit: Patients with prostate cancer who do not have issues with androgen receptor signaling or degradation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that overcome resistance to current prostate cancer treatments.
How similar studies have performed: Other research has shown promising results in targeting similar mechanisms of protein degradation in cancer treatment, indicating potential for success in this approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Mu, Ping — Yale University
- Study coordinator: Mu, Ping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.